Clinical Trial Detail

NCT ID NCT01463046
Title Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, San Francisco
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin + Panobinostat

Age Groups: adult

No variant requirements are available.